Where can researchers source third-party tested Tesamorelin?

Midwest Peptide supplies research-grade Tesamorelin with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

Tesamorelin Lean Mass Research | Midwest Peptide

Tesamorelin Metabolic Syndrome Research: Multi-Endpoint DataPrev|CJC/Ipa Lean Mass Research: Body Composition EndpointsNext

Tesamorelin Lean Mass Research: Muscle Preservation Studies

Q: Is Tesamorelin approved for human use?

No. Tesamorelin is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Tesamorelin · Published April 24, 2026 · Updated May 18, 2026 · 9 min read

Quick Answer

Tesamorelin lean mass research examines muscle preservation and body composition outcomes in rodent and clinical research contexts. Studies measure lean tissue accretion, muscle protein dynamics, and body composition biomarkers across standardized research protocols using this stabilized GHRH analog. For research use only, not for human consumption.

Tesamorelin Lean Mass Research: Muscle Preservation Studies

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Growth Hormone and Muscle Preservation
Body Composition in Lipodystrophy Research
Preclinical Rodent Body Composition Data
Muscle Quality Research
Comparison With Other GHRH Analogs
Integration With Metabolic Endpoint Research
Age Related Muscle Loss Context
Research Peptides Referenced
Related Research Reading
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

Tesamorelin lean mass research addresses the skeletal muscle preservation and body composition effects of the GHRH analog in preclinical and clinical research models. The existing CJC-1295 / Ipamorelin Blend: What Researchers Need to Know documents the upstream endocrine pharmacology including GHRH chemistry, visceral fat reduction, IGF-1 axis activation, lipolysis, and lipodystrophy clinical data. This article focuses on the downstream lean tissue effects that complement the visceral fat findings and complete the body composition picture.

Frequently Asked Questions

What is Tesamorelin in research contexts?

Tesamorelin is a synthetic GHRH analog with a hexenoyl modification at the N-terminus that confers DPP-IV resistance. It is studied in preclinical and clinical research for visceral adipose tissue, IGF-1 axis biology, and growth hormone pulse dynamics.

How does Tesamorelin support muscle preservation?

Through GH/IGF-1 axis activation, Tesamorelin supports muscle protein synthesis, satellite cell activation, and lean mass preservation. Research models report preserved or increased lean mass with chronic dosing alongside reduced visceral adipose tissue, particularly in catabolic conditions.

What lean mass endpoints are measured with Tesamorelin?

Endpoints include DEXA, MRI, and quantitative magnetic resonance for body composition, grip strength, muscle cross-sectional area on imaging, gastrocnemius mass on dissection, and biochemical markers of muscle protein synthesis and breakdown.

Is Tesamorelin approved for human use?

Glossary

Key terms used in this article.

GHRH Analog: A synthetic peptide modeled on growth hormone-releasing hormone with structural changes that improve stability or pharmacokinetics.
Visceral Adipose Tissue (VAT): Fat depots surrounding internal abdominal organs, distinct from subcutaneous fat and metabolically more active.
DPP-IV: Dipeptidyl peptidase IV, the enzyme that rapidly inactivates many peptide hormones including native GHRH and GLP-1.
IGF-1: Insulin-like growth factor 1, the primary downstream mediator of growth hormone action and a biomarker for GHRH analog efficacy.
Lipodystrophy: Abnormal distribution or loss of body fat, including the visceral adiposity associated with HIV antiretroviral therapy.
Lean Mass: Body mass excluding fat, including skeletal muscle, organs, bone, and water.
Satellite Cell: Quiescent muscle stem cells that activate after injury or growth stimulation to support muscle regeneration and hypertrophy.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. Tesamorelin is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.

Growth Hormone and Muscle Preservation

The growth hormone axis is one of the primary endocrine regulators of lean body mass. Growth hormone signaling through the JAK2 STAT5 pathway in skeletal muscle promotes protein synthesis, supports nitrogen retention, and facilitates amino acid uptake. These anabolic effects operate through both direct growth hormone receptor signaling on muscle cells and through the downstream IGF-1 production documented in the Tesamorelin Metabolic Syndrome Research: Multi-Endpoint Data.

Tesamorelin stimulates endogenous growth hormone release through the GHRH receptor pathway as documented in the Tesamorelin/Ipamorelin Blend in Research: Combining GHRH and GHRP Mechanisms. The pulsatile growth hormone profile produced by tesamorelin is particularly important for lean mass effects because pulsatile growth hormone signaling maintains hepatic and peripheral responsiveness better than continuous exposure, which leads to progressive desensitization as discussed in the CJC-1295 DAC vs No DAC article in the adjacent cluster.

The Nature subject hub on growth hormone and the ScienceDirect muscle protein synthesis topic page archive primary research on the integration of growth hormone signaling with muscle biology.

Body Composition in Lipodystrophy Research

The tesamorelin lipodystrophy article covers the clinical trial literature on visceral adipose tissue reduction. Within that same research context, lean mass was measured as a secondary endpoint, and the published data documents preservation of lean mass during the visceral fat reduction. This is an important finding because many interventions that reduce visceral fat also reduce lean mass as part of the overall weight loss, which would be undesirable.

The lean mass preservation during tesamorelin mediated visceral fat reduction reflects the anabolic lean tissue effects of growth hormone signaling operating simultaneously with the lipolytic effects on adipose tissue documented in the lipolysis article. The net body composition change is therefore a shift from fat mass to lean mass rather than a simple reduction in total mass.

Published body composition data from the lipodystrophy trials shows that tesamorelin treated groups maintained lean mass at baseline levels or above while reducing visceral adipose mass. This preservation contrasts with the expected decline in lean mass that would accompany comparable total weight reduction from caloric restriction alone. The growth hormone mediated lean mass support is the mechanistic explanation for this favorable body composition shift.

Preclinical Rodent Body Composition Data

Beyond the clinical trial data, rodent research on tesamorelin body composition has used DEXA, micro CT, and tissue dissection to characterize the lean versus fat compartment effects under controlled experimental conditions. The rodent data generally aligns with the clinical findings, with treated animals showing maintained or increased lean mass alongside reduced fat mass.

The rodent studies provide additional mechanistic detail not available from clinical trials. Muscle specific protein synthesis rates measured by isotope tracer methods document increased synthesis in tesamorelin treated animals. Muscle fiber cross sectional area measurements from histological sections document increased fiber size. Gene expression analysis of muscle tissue documents upregulation of IGF-1 signaling pathway components and protein synthesis regulatory genes.

The rodent body composition data also extends the clinical findings to different metabolic contexts. Diet induced obese rodent models, aged rodent models, and corticosteroid induced catabolic models have all been used to examine tesamorelin lean mass effects under different physiological conditions. The consistency of the lean mass preservation across these diverse models strengthens the interpretation that the effect is a robust consequence of growth hormone axis activation rather than an artifact of any specific model.

The Wiley Online Library body composition collection and the Frontiers in Endocrinology open access journal archive primary research on body composition methodology and on growth hormone axis effects on muscle and adipose tissue.

Muscle Quality Research

Lean mass quantity is only part of the body composition picture. Muscle quality, defined as the functional capacity per unit of muscle mass, is an additional endpoint that captures whether the lean tissue is functionally competent. Research on tesamorelin has examined muscle quality endpoints including force production per unit cross sectional area, myosin heavy chain isoform distribution, and mitochondrial density in muscle tissue.

Published data documents preserved or improved muscle quality in tesamorelin treated animals compared to controls in models where muscle quality would otherwise decline, such as aging models and catabolic models. The quality data supports the interpretation that tesamorelin mediated lean mass preservation produces functionally useful tissue rather than merely increasing the measured mass without corresponding functional capacity.

The muscle quality perspective connects to the exercise and physical function research that is part of the growth hormone research literature. Growth hormone axis stimulation supports not just static lean mass but also the metabolic and contractile properties that determine how effectively the muscle performs under dynamic conditions.

Comparison With Other GHRH Analogs

The Tesamorelin GHRH Analog Chemistry: What Makes Tesamorelin Stable in Research provides the pharmacological framework for comparing GHRH analogs. For lean mass endpoints specifically, both tesamorelin and CJC-1295 No DAC plus ipamorelin produce similar directional effects because they both stimulate endogenous growth hormone release through the GHRH receptor pathway. The CJC/Ipa lean mass article covers the lean mass data from the CJC/Ipa perspective.

The specific quantitative differences between the two GHRH analogs on lean mass endpoints reflect differences in their pharmacokinetic profiles, receptor binding characteristics, and the resulting growth hormone pulse patterns. Head to head comparative research under controlled conditions provides the most informative data for distinguishing the compounds on lean mass endpoints.

Midwest Peptide supplies both Tesamorelin 10mg and the CJC-1295/Ipamorelin Blend 10mg for research that wants to compare GHRH analog approaches. The Tesa/Ipa 10mg Blend provides a combined formulation that uses tesamorelin as the GHRH component alongside ipamorelin.

Integration With Metabolic Endpoint Research

The lean mass effects integrate with the metabolic research covered elsewhere in the cluster. Lean mass is the primary insulin sensitive tissue compartment, and changes in lean mass affect whole body insulin sensitivity and glucose disposal. Increased lean mass from tesamorelin mediated growth hormone signaling increases the glucose disposal capacity, which contributes to the metabolic improvements documented in the lipodystrophy research.

The metabolic integration also extends to the lipolysis effects covered in the lipolysis article. The fatty acids released from adipose lipolysis under growth hormone stimulation are used as fuel by the increased lean mass, which provides a metabolic sink for the mobilized lipids. The coordinated shift in both compartments produces a more favorable metabolic profile than either change alone would produce.

The connection to the incretin receptor agonist research in adjacent clusters is worth noting. GLP-1 SM, GLP-2 TZ, and GLP-3 RT also affect body composition but through reduced food intake rather than through growth hormone mediated anabolic effects. The lean mass preservation profile differs between growth hormone secretagogues and incretin agonists, and comparative research across these compound classes can characterize the different approaches to body composition modulation.

The Cell Press journal Cell Metabolism and the ScienceDirect body composition topic page archive primary research on the integrated metabolic biology of body composition.

Tesamorelin lean mass research has particular relevance to age related muscle loss research. The growth hormone axis declines with age, and this decline contributes to the progressive lean mass loss that defines sarcopenia. Tesamorelin administration in aged rodent models partially restores the growth hormone axis activity and partially attenuates the age related lean mass decline.

The partial restoration is consistent with the observation that growth hormone axis decline is one of several contributors to age related lean mass loss. Other contributors including reduced physical activity, altered inflammatory biology, mitochondrial dysfunction, and reduced satellite cell function are not directly addressed by growth hormone axis restoration. Multi intervention approaches that combine growth hormone axis stimulation with other interventions may be more effective than single interventions alone.

The aging context connects to the broader aging peptide research across the Midwest Peptide catalog, including the MOTS-c aging article, the NAD+ in Research: A Comprehensive Review of Nicotinamide Adenine Dinucleotide Studies, and the GHK-Cu skin aging article. Each addresses a different aspect of the aging phenotype, and integrated research programs can examine the interactions between these different interventional approaches.

Research Peptides Referenced

Tesamorelin 10mg, research grade GHRH analog, third party COA
Tesa/Ipa 10mg Blend, tesamorelin plus ipamorelin combination
CJC-1295/Ipamorelin Blend 10mg, alternative GHRH/GHRP combination
GLP-1 SM 20mg, incretin agonist for comparison
MOTS-c 10mg, mitochondrial peptide

For complete sourcing details see the Tesamorelin sourcing guide.

Within the Tesamorelin cluster:

Related clusters:

Not for human consumption. Research use only.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

MOTS-C 10mg, 99%+ purity, COA included
Tesamorelin 10mg, 99%+ purity, COA included
NAD+ 500mg, 99%+ purity, COA included
GLP-1 SM 20mg, 99%+ purity, COA included
GHK-Cu 50mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

Tesamorelin Lean Mass Research: Muscle Preservation Studies

Frequently Asked Questions

What is Tesamorelin in research contexts?

How does Tesamorelin support muscle preservation?

What lean mass endpoints are measured with Tesamorelin?

Is Tesamorelin approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Growth Hormone and Muscle Preservation

Body Composition in Lipodystrophy Research

Preclinical Rodent Body Composition Data

Muscle Quality Research

Comparison With Other GHRH Analogs

Integration With Metabolic Endpoint Research

Research Peptides Referenced

Ready to Start Your Research?

Where can researchers source third-party tested Tesamorelin?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

Tesamorelin Lean Mass Research: Muscle Preservation Studies

Frequently Asked Questions

What is Tesamorelin in research contexts?

How does Tesamorelin support muscle preservation?

What lean mass endpoints are measured with Tesamorelin?

Is Tesamorelin approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Growth Hormone and Muscle Preservation

Body Composition in Lipodystrophy Research

Preclinical Rodent Body Composition Data

Muscle Quality Research

Comparison With Other GHRH Analogs

Integration With Metabolic Endpoint Research

Age Related Muscle Loss Context

Research Peptides Referenced

Related Research Reading

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested Tesamorelin?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?